385 research outputs found
PCVII COST EFFECTIVENESS OF ADDING NIASPANTO ATORVASTATIN TREATMENT IN THE SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE IN PATIENTS WITH DYSLIPIDEMIA IN THE UK
Get PDFPDB52 TYPE-2 DIABETES MODELS THAT DO NOT ACCOUNT FOR MICROVASCULAR DISEASE SCREENING RATESAND IMPORTANT CONCOMITANT MEDICATION USE MAY LEAD TO SUBSTANTIAL MISREPRESENTATION OF THE COST-EFFECTIVENESS OF NEW MEDICATIONS
Get PDFDB6 COMPARISON OF THE COST-EFFECTIVENESS FOR BASAL-BOLUS THERAPY OF TYPE-1 DIABETES USING INSULIN DETEMIR+ INSULIN ASPART OR HUMAN INSULIN-BASED REGIMENS IN THE NETHERLANDS
Get PDFPDB23 ECONOMIC EVALUATION OF DETEMIR-BASED BASAL/BOLUS THERAPY VERSUS NPH-BASED BASAL/BOLUS THERAPY FOR TYPE-1 DIABETES IN GERMANY
Get PDFPCV31 HEALTH ECONOMIC ASSESSMENT OF RAISING HDL-C WITH PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) WHEN ADDED TO STATIN THERAPY IN PATIENTS WITH DYSLIPIDEMIA AND TYPE 2 DIABETES:AN ANALYSIS FOR SWEDEN
Get PDFMD1 HEALTH ECONOMIC ANALYSIS OF CONTINUOUS SUBCUTANEOUS INSULIN INFUSION COMPARED TO MULTIPLE DAILY INJECTIONS FOR THE TREATMENT OF TYPE 1 DIABETES IN POLAND
Get PDFPDB9 PROJECTED IMPACT ON CORONARY HEART DISEASE AT 5, 10 AND 35 YEARS OF ADDING PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) TO STATIN TREATMENT IN PATIENTS WITH TYPE-2 DIABETES
Get PDFPDB20 BIPHASIC INSULIN ASPART 30 VERSUS ORAL HYPOGLYCEMIC AGENTS IN THE TREATMENT OF TYPE-2 DIABETES: LONG-TERM PROJECTION OF CLINICAL AND COST OUTCOMES IN SWEDEN
Get PDFPDB8 CLINICAL BENEFITS OF PROLONGED-RELEASE NICOTINIC ACID (NIASPAN®) AND EZETIMIBE IN STATIN-TREATED TYPE-2 DIABETES PATIENTS FAILING TO REACH TARGET CHOLESTEROL LEVELS
Get PDFPDB25 FIXED COMBINATION METFORMIN PLUS GLIBENCLAMIDE (GLUCOVANCE®) IS COST AND LIFE SAVING COMPARED TO METFORMIN PLUS ROSIGLITAZONE IN TYPE-2 DIABETES PATIENTS IN FRANCE
Get PDF- …
